Results 21 to 30 of about 233 (110)

Thyronamines—Past, Present, and Future [PDF]

Endocrine Reviews, 2011
Thyronamines (TAMs) are a newly identified class of endogenous signaling compounds. Their structure is identical to that of thyroid hormone and deiodinated thyroid hormone derivatives, except that TAMs do not possess a carboxylate group. Despite some initial publications dating back to the 1950s, TAMs did not develop into an independent area of ...
S, Piehl, C S, Hoefig, T S, Scanlan, J, Köhrle   +3 more
openaire   +2 more sources

Thyronamines Are Substrates for Human Liver Sulfotransferases [PDF]

Endocrinology, 2007
Sulfotransferases (SULTs) catalyze the sulfation of many endogenous compounds that include monoamine neurotransmitters, such as dopamine (DA), and thyroid hormones (iodothyronines). Decarboxylation of iodothyronines results in formation of thyronamines.
C A, Pietsch, T S, Scanlan, R J, Anderson   +2 more
openaire   +2 more sources

Central effects of thyronamines on glucose metabolism in rats [PDF]

Journal of Endocrinology, 2009
Thyronamines are naturally occurring, chemical relatives of thyroid hormone. Systemic administration of synthetic 3-iodothyronamine (T 1 AM) and – to a lesser extent – thyronamine (T 0 AM), leads to acute bradycardia, hypothermia, decreased metabolic ...
Klieverik, Lars P., Foppen, Ewout, Ackermans, Mariëtte T., Serlie, Mireille J., Sauerwein, Hans P., Scanlan, Thomas S., Grandy, David K., Fliers, Eric, Kalsbeek, Andries   +8 more
openaire   +5 more sources

Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics

Data in Brief, 2020
In order to rapidly identify the phenotypic profile and possible off-target liability effects of novel synthesized thyromimetics for selection of lead compounds for further optimization studies, we performed in vitro screening on a new small library of ...
Massimiliano Runfola, Simona Sestito, Sheraz Gul, Grazia Chiellini, Simona Rapposelli   +4 more
doaj   +1 more source

Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway. [PDF]

Int J Mol Sci, 2019
3-Iodothyronamine (T1AM) and its synthetic analog SG-2 are rapidly emerging as promising drivers of cellular metabolic reprogramming. Our recent research indicates that in obese mice a sub-chronic low dose T1AM treatment increased lipolysis, associated with significant weight loss independent of food consumption. The specific cellular mechanism of T1AM’
Rogowski M, Bellusci L, Sabatini M, Rapposelli S, Rahman SM, Chiellini G, Assadi-Porter FM.   +6 more
europepmc   +4 more sources

Dopamine synthesis and dopamine receptor expression are disturbed in recurrent miscarriages

Endocrine Connections, 2018
Objectives: l-dopa decarboxylase (DDC) is responsible for the synthesis of dopamine. Dopamine, which binds to the D2-dopamine receptor (D2R), plays an important role in the maintenance of pregnancy.
Michael J Gratz, Stavroula Stavrou, Christina Kuhn, Simone Hofmann, Kerstin Hermelink, Helene Heidegger, Stefan Hutter, Doris Mayr, Sven Mahner, Udo Jeschke, Aurelia Vattai   +10 more
doaj   +1 more source

Tissue thyroid hormones and thyronamines

Heart Failure Reviews, 2016
It has been known for a long time that changes in cardiac function are a major component of the clinical presentation of thyroid disease. Increased heart rate and hyperdynamic circulation are hallmarks of hyperthyroidism, while bradycardia and decreased contractility characterize hypothyroidism.
ACCORRONI, ALICE, SAPONARO, FEDERICA, ZUCCHI, RICCARDO   +2 more
openaire   +3 more sources

Thyronamines are isozyme-specific substrates of deiodinases. [PDF]

Endocrinology, 2008
3-Iodothyronamine (3-T 1 AM) and thyronamine (T AM) are novel endogenous signaling molecules that exhibit great structural similarity to thyroid hormones but apparently antagonize classical thyroid hormone (T(3)) actions. Their proposed biosynthesis from thyroid hormones would require decarboxylation and more or less extensive deiodination. Deiodinases
Piehl S, Heberer T, Balizs G, Scanlan TS, Smits R, Koksch B, Köhrle J.   +6 more
europepmc   +3 more sources

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors

British Journal of Pharmacology, Volume 176, Issue S1, Page S21-S141, December 2019., 2019
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www ...
Stephen P H Alexander, Arthur Christopoulos, Anthony P Davenport, Eamonn Kelly, Alistair Mathie, John A Peters, Emma L Veale, Jane F Armstrong, Elena Faccenda, Simon D Harding, Adam J Pawson, Joanna L Sharman, Christopher Southan, Jamie A Davies, CGTP Collaborators, Maria P Abbracchio, Wayne Alexander, Khaled Al-hosaini, Magnus Bäck, Jean‐Martin Beaulieu, Kenneth E. Bernstein, Bernhard Bettler, Nigel JM Birdsall, Victoria Blaho, Corinne Bousquet, Hans Bräuner-Osborne, Geoffrey Burnstock, Girolamo Caló, Justo P Castaño, Kevin J Catt, Stefania Ceruti, Paul Chazot, Nan Chiang, Jerold Chun, Antonia Cianciulli, Lucie H Clapp, Réjean Couture, Zsolt Csaba, Gordon Dent, Khuraijam Dhanachandra Singh, Steven D Douglas, Pascal Dournaud, Satoru Eguchi, Emanuel Escher, Edward Filardo, Tung M Fong, Marta Fumagalli, Raul R Gainetdinov, Marc de Gasparo, Marvin Gershengorn, Fernand Gobeil, Theodore L Goodfriend, Cyril Goudet, Karen J Gregory, Andrew L Gundlach, Jörg Hamann, Julien Hanson, Richard L Hauger, Debbie Hay, Akos Heinemann, Morley D Hollenberg, Nicholas D Holliday, Mastgugu Horiuchi, Daniel Hoyer, László Hunyady, Ahsan Husain, Adriaan P Ijzerman, Tadashi Inagami, Kenneth A Jacobson, Robert T Jensen, Ralf Jockers, Deepa Jonnalagadda, Sadashiva Karnik, Klemens Kaupmann, Jacqueline Kemp, Charles Kennedy, Yasuyuki Kihara, Paweł Kozielewicz, Hans‐Jürgen Kreienkamp, Jyrki P Kukkonen, Tobias Langenhan, Katie Leach, Davide Lecca, John D Lee, Susan E Leeman, Jérôme Leprince, Stephen J Lolait, Amelie Lupp, Robyn Macrae, Janet Maguire, Jean Mazella, Craig A McArdle, Shlomo Melmed, Martin C Michel, Laurence Miller, Vincenzo Mitolo, Bernard Mouillac, Philip M Murphy, Jean‐Louis Nahon, Xavier Norel, Duuamene Nyimanu, Anne‐Marie O'Carroll, Stefan Offermanns, Maria A Panaro, Roger G Pertwee, Jean‐Philippe Pin, Eric Prossnitz, Rithwik Ramachandran, Rainer K Reinscheid, Philippe Rondard, G Enrico Rovati, Chiara Ruzza, Gareth Sanger, Torsten Schöneberg, Gunnar Schulte, Stefan Schulz, Deborah L Segaloff, Charles N Serhan, Leigh A Stoddart, Yukihiko Sugimoto, Roger Summers, Valerie Tan, Walter Thomas, Pieter BMWM Timmermans, Kalyan Tirupula, Giovanni Tulipano, Hamiyet Unal, Thomas Unger, Patrick Vanderheyden, David Vaudry, Hubert Vaudry, Jean‐Pierre Vilardaga, Christopher S Walker, Donald T Ward, Hans‐Jürgen Wester, Gary B Willars, Tom Lloyd Williams, Trent M Woodruff, Chengcan Yao   +138 more
wiley   +1 more source

Lessons from Randomised Clinical Trials for Triiodothyronine Treatment of Hypothyroidism: Have They Achieved Their Objectives?

Journal of Thyroid Research, Volume 2018, Issue 1, 2018., 2018
Randomised controlled trials are deemed to be the strongest class of evidence in evidence‐based medicine. Failure of trials to prove superiority of T3/T4 combination therapy over standard LT4 monotherapy has greatly influenced guidelines, while not resolving the ongoing debate.
Rudolf Hoermann, John E. M. Midgley, Rolf Larisch, Johannes W. Dietrich, Massimo Tonacchera   +4 more
wiley   +1 more source